1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
WuXi Biologics (Cayman) Inc.

WuXi Biologics (Cayman) Inc.

2269.HK
WuXi Biologics (Cayman) Inc.HK flagHong Kong Stock Exchange
37.96
HKD
+0.90
- -
157.28BMarket Cap
WuXi Biologics (Cayman) Inc.
2269.HK
(Hong Kong Stock Exchange)

Recent

price

37.96

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.1
0.16
0.29
0.5
0.7
1.07
1.42
2.47
3.66
4.09
4.57
5.41
Revenue per Share
0.01
0.01
0.04
0.08
0.17
0.27
0.43
0.81
1.06
0.82
0.82
1.22
Basic EPS, GAAP
-0.01
-0.07
-0.1
-0.1
-0.29
-0.55
-1.05
-0.74
-0.08
0.11
0.32
0.65
Free Cash Flow per Basic Share
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.01
0.01
0.05
0.12
0.27
0.51
- -
- -
2.52
3.24
4.01
5.17
Book Value per Share
0.11
0.04
0.08
1.25
2.06
3.31
5.14
7.33
8.18
10.08
10.66
12.67
Tangible Book Value per Share
3,402
3,402
3,402
3,222
3,632
3,717
3,953
4,174
4,173
4,164
4,082
4,027
Basic Weighted Avg Shares
332
557
989
1,619
2,534
3,984
5,612
10,290
15,269
17,034
18,675
21,790
Sales/Revenue/Turnover
15.34
10.75
22.97
27.82
27.39
26.53
31.39
33.67
31.43
26.12
26.63
32.39
Operating Margin (%)
42
57
93
87
144
221
303
482
801
1,169
1,437
1,448
Depreciation Expense
42
45
141
253
631
1,014
1,689
3,388
4,420
3,400
3,356
4,908
Net Income, GAAP
14.35
31.95
19.76
16.81
14.54
10.32
13.89
12.13
15.08
14.45
18.39
21
Effective Tax Rate (%)
12.65
7.99
14.27
15.61
24.88
25.45
30.09
32.93
28.95
19.96
17.97
22.53
Profit Margin (%)
-32
-601
29
2,235
4,426
6,801
9,706
11,274
9,151
13,562
14,952
19,828
Working Capital
- -
- -
896
- -
- -
1,661
2,504
2,070
2,951
3,830
2,321
1,849
LT Debt
372
146
270
4,024
7,994
12,896
20,899
32,706
36,213
44,018
45,478
53,039
Total Equity
- -
7.72
17.93
13.77
9.84
8.17
7.68
9.88
10.42
8.51
8.23
10.51
Return on Invested Capital (%)
- -
16.01
17.9
33.42
92.94
40.21
43.86
78.73
41.73
17.78
12.4
15.35
Return on Capital (%)
- -
134.46
135.66
90.2
92.95
71.36
179.73
1,473,251.3
84.06
28.33
22.49
26.41
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
180.39%
21.74%
16.63%
Free Cash Flow
41.58%
-10.36%
102.32%
Net Income, GAAP
72.6%
30.59%
46.25%
Sales/Revenue/Turnover
46.55%
33.92%
16.68%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
17,034
2024
- -
- -
- -
- -
18,675
2025
- -
- -
- -
- -
21,790

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.82
2024
- -
- -
- -
- -
0.82
2025
- -
- -
- -
- -
1.22

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Formycon AG (FYB.DE)
ImageneBio Inc (IMA)
Allarity Therapeutics, Inc. (ALLR)
United Therapeutics Corporation (UTHR)
Jiangsu Aidea Pharmaceutical Co., Ltd. (688488.SS)
Awakn Life Sciences Corp. (AWKNF)
Business
WuXi Biologics (Cayman) Inc. WuXi Biologics (Cayman) Inc. (2269.HK) is a leading global contract research, development and manufacturing organization (CRDMO) that provides comprehensive end-to-end biologics solutions, including biologics discovery, cell line development, process and product development, analytical testing, clinical and commercial cGMP manufacturing of drug substances and drug products, as well as advanced modalities such as antibody-drug conjugates via its subsidiary WuXi XDC; the company leverages proprietary technology platforms like WuXia cell line development (including the recently launched WuXia 4.0 with TrueSite TI targeted integration platform in September 2025 for accelerated high-titer biologics and WuXiHigh 2.0 in June 2025 for high-concentration formulations up to 230 mg/mL), WuXiBody for multispecific antibodies, and others for bispecific T-cell engagers, fusion proteins, and Fab fragments. Founded in 2010 and headquartered in Wuxi, China, WuXi Biologics operates extensive manufacturing facilities across China (Wuxi, Suzhou, Hangzhou), the United States, Ireland (Dundalk), Germany (Wuppertal), and Singapore, serving top global pharmaceutical and biotech companies with a focus on complex biologics for oncology, autoimmune, and inflammatory diseases. Recent developments include a January 2025 partnership with Candid Therapeutics granting exclusive global rights to preclinical tri-specific T-cell engager antibodies from its WuXiBody platform (up to $925 million in milestones plus royalties), solid 2025 interim results with 24.9% YoY commercial manufacturing revenue growth, addition of 86 new integrated projects bringing the total to 864 (including record pre-clinical and early-phase pipelines), expansion of global capacity to mitigate supply chain risks, and GMP release of the new DP3 drug product facility at its Wuxi site in August 2025.

Company News

APIChatGPT

  • headlinesoftoday.com

    WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities

  • headlinesoftoday.com

    WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts